ArriVent Net Invested Capital from 2010 to 2024
| AVBP Stock | 27.45 0.86 3.23% |
Net Invested Capital | First Reported 2010-12-31 | Previous Quarter -137.9 M | Current Value -144.8 M | Quarterly Volatility 40 M |
Check ArriVent BioPharma, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ArriVent BioPharma,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.7 M, Selling General Administrative of 7 M or Selling And Marketing Expenses of 603.2 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.01. ArriVent financial statements analysis is a perfect complement when working with ArriVent BioPharma, Valuation or Volatility modules.
ArriVent | Net Invested Capital |
Latest ArriVent BioPharma,'s Net Invested Capital Growth Pattern
Below is the plot of the Net Invested Capital of ArriVent BioPharma, Common over the last few years. It is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. ArriVent BioPharma,'s Net Invested Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ArriVent BioPharma,'s overall financial position and show how it may be relating to other accounts over time.
| Net Invested Capital | 10 Years Trend |
|
Net Invested Capital |
| Timeline |
ArriVent Net Invested Capital Regression Statistics
| Arithmetic Mean | (70,401,806) | |
| Coefficient Of Variation | (56.77) | |
| Mean Deviation | 31,911,448 | |
| Median | (48,644,000) | |
| Standard Deviation | 39,964,987 | |
| Sample Variance | 1597.2T | |
| Range | 104.5M | |
| R-Value | (0.75) | |
| Mean Square Error | 752.3T | |
| R-Squared | 0.56 | |
| Significance | 0 | |
| Slope | (6,703,025) | |
| Total Sum of Squares | 22360.8T |
ArriVent Net Invested Capital History
About ArriVent BioPharma, Financial Statements
ArriVent BioPharma, shareholders use historical fundamental indicators, such as Net Invested Capital, to determine how well the company is positioned to perform in the future. Although ArriVent BioPharma, investors may analyze each financial statement separately, they are all interrelated. The changes in ArriVent BioPharma,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on ArriVent BioPharma,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Invested Capital | -137.9 M | -144.8 M |
Pair Trading with ArriVent BioPharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ArriVent BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma, will appreciate offsetting losses from the drop in the long position's value.Moving against ArriVent Stock
| 0.71 | MTEM | Molecular Templates | PairCorr |
| 0.67 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.62 | TPST | Tempest Therapeutics | PairCorr |
| 0.6 | ME | 23Andme Holding | PairCorr |
| 0.57 | AGL | agilon health | PairCorr |
The ability to find closely correlated positions to ArriVent BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ArriVent BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ArriVent BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ArriVent BioPharma, Common to buy it.
The correlation of ArriVent BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ArriVent BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ArriVent BioPharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ArriVent BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.